CR20140550A - Formulaciones antibióticas inyectables y sus métodos de uso - Google Patents

Formulaciones antibióticas inyectables y sus métodos de uso

Info

Publication number
CR20140550A
CR20140550A CR20140550A CR20140550A CR20140550A CR 20140550 A CR20140550 A CR 20140550A CR 20140550 A CR20140550 A CR 20140550A CR 20140550 A CR20140550 A CR 20140550A CR 20140550 A CR20140550 A CR 20140550A
Authority
CR
Costa Rica
Prior art keywords
methods
antibiotic formulations
injectable antibiotic
injectable
formulations
Prior art date
Application number
CR20140550A
Other languages
English (en)
Spanish (es)
Inventor
Al Alawi Fadil
Bork Olaf
George Tucker Ian
Jain Rohit
Nanjan Karthigeyan
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49949085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140550(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NZ613138A external-priority patent/NZ613138B2/en
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of CR20140550A publication Critical patent/CR20140550A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CR20140550A 2012-07-17 2014-12-02 Formulaciones antibióticas inyectables y sus métodos de uso CR20140550A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ60129912 2012-07-17
NZ61017513 2013-05-03
NZ613138A NZ613138B2 (en) 2013-07-12 Injectable antibiotic formulations and their methods of use
PCT/NZ2013/000123 WO2014014363A1 (en) 2012-07-17 2013-07-16 Injectable antibiotic formulations and their methods of use

Publications (1)

Publication Number Publication Date
CR20140550A true CR20140550A (es) 2015-02-05

Family

ID=49949085

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140550A CR20140550A (es) 2012-07-17 2014-12-02 Formulaciones antibióticas inyectables y sus métodos de uso

Country Status (30)

Country Link
US (1) US10376585B2 (cg-RX-API-DMAC10.html)
EP (1) EP2874624B8 (cg-RX-API-DMAC10.html)
JP (1) JP6189437B2 (cg-RX-API-DMAC10.html)
KR (1) KR102113822B1 (cg-RX-API-DMAC10.html)
CN (1) CN104470517B (cg-RX-API-DMAC10.html)
AU (1) AU2013290826B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014031083B1 (cg-RX-API-DMAC10.html)
CA (1) CA2875351C (cg-RX-API-DMAC10.html)
CL (1) CL2014003423A1 (cg-RX-API-DMAC10.html)
CO (1) CO7240359A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140550A (cg-RX-API-DMAC10.html)
DK (1) DK2874624T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2014000288A (cg-RX-API-DMAC10.html)
ES (1) ES2752034T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20191730T1 (cg-RX-API-DMAC10.html)
HU (1) HUE046427T2 (cg-RX-API-DMAC10.html)
IL (1) IL236713B (cg-RX-API-DMAC10.html)
LT (1) LT2874624T (cg-RX-API-DMAC10.html)
MX (2) MX387668B (cg-RX-API-DMAC10.html)
MY (1) MY172561A (cg-RX-API-DMAC10.html)
NI (1) NI201400152A (cg-RX-API-DMAC10.html)
PH (1) PH12014502716B1 (cg-RX-API-DMAC10.html)
PL (1) PL2874624T3 (cg-RX-API-DMAC10.html)
PT (1) PT2874624T (cg-RX-API-DMAC10.html)
RU (1) RU2643327C2 (cg-RX-API-DMAC10.html)
SI (1) SI2874624T1 (cg-RX-API-DMAC10.html)
SV (1) SV2014004882A (cg-RX-API-DMAC10.html)
UA (1) UA118654C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014014363A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201409322B (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729328T3 (es) * 2012-12-20 2019-10-31 Alleva Animal Health Ltd Formulaciones inyectables veterinarias de penetamato

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49768B1 (en) 1979-05-21 1985-12-11 Leo Pharm Prod Ltd 6beta-halopenicillanic acid derivatives
IE51516B1 (en) * 1980-10-06 1987-01-07 Leo Pharm Prod Ltd 1,1-dioxapenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate napsylate
IL64009A (en) 1980-10-31 1984-09-30 Rech Applications Therap Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them
IE51846B1 (en) 1980-11-17 1987-04-15 Leo Pharm Prod Ltd Pharmaceutical preparation for veterinary use and an appliance containing it
EP0115001B1 (de) 1982-12-28 1988-06-15 Bayer Ag Stabile Aminoglykosid-Penicillin-Injektionsformulierungen
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
CH693625A5 (it) * 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
US20040022815A1 (en) 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US6911441B2 (en) 2002-12-16 2005-06-28 Akzo Nobel N.V. Prolonged release pharmaceutical composition
CN1517090A (zh) 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US20050143347A1 (en) * 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
DE102004025324A1 (de) * 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US8679540B2 (en) * 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
PL2214656T3 (pl) * 2007-10-26 2019-06-28 Avivagen Inc. Kompozycje i sposoby wzmacniania odpowiedzi immunologicznej
HRP20140939T1 (hr) * 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CN101822637A (zh) 2009-12-31 2010-09-08 天津瑞普生物技术股份有限公司 一种含有β-内酰胺类抗生素的混悬注射剂
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
DE102010015143A1 (de) 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
EP2723335A4 (en) * 2011-06-23 2015-01-07 Bayer New Zealand Ltd ANTIPARASITIC COMPOSITION WITH A MACROCYCLIC LACTON AND LEVAMISOL AND METHOD FOR THE TREATMENT OF PARASITIC ATTACK
AU2012359296B2 (en) 2011-12-23 2014-12-11 Elanco New Zealand Antibiotic formulations
WO2013129944A1 (en) * 2012-02-27 2013-09-06 Bayer New Zealand Limited Controlled release compositions and their methods of use

Also Published As

Publication number Publication date
SV2014004882A (es) 2016-11-11
HRP20191730T1 (hr) 2019-12-13
MY172561A (en) 2019-12-03
MX387668B (es) 2025-03-18
HUE046427T2 (hu) 2020-03-30
KR102113822B1 (ko) 2020-05-22
EP2874624A4 (en) 2015-12-02
DK2874624T3 (da) 2019-11-11
JP2015522608A (ja) 2015-08-06
BR112014031083B1 (pt) 2021-06-15
RU2643327C2 (ru) 2018-01-31
IL236713B (en) 2018-05-31
ZA201409322B (en) 2015-12-23
AU2013290826A1 (en) 2015-01-15
LT2874624T (lt) 2019-12-10
UA118654C2 (uk) 2019-02-25
IL236713A0 (en) 2015-02-26
NI201400152A (es) 2015-03-27
CL2014003423A1 (es) 2015-04-17
EP2874624B8 (en) 2019-10-02
PH12014502716A1 (en) 2015-02-02
PT2874624T (pt) 2019-11-04
CN104470517A (zh) 2015-03-25
PL2874624T3 (pl) 2020-07-27
MX358248B (es) 2018-08-10
WO2014014363A1 (en) 2014-01-23
BR112014031083A2 (pt) 2017-06-27
AU2013290826B2 (en) 2018-10-18
EP2874624A1 (en) 2015-05-27
MX2014015927A (es) 2015-03-03
PH12014502716B1 (en) 2015-02-02
CA2875351C (en) 2021-08-31
US20150174248A1 (en) 2015-06-25
CO7240359A2 (es) 2015-04-17
DOP2014000288A (es) 2015-02-15
SI2874624T1 (sl) 2020-02-28
JP6189437B2 (ja) 2017-08-30
US10376585B2 (en) 2019-08-13
RU2015105251A (ru) 2016-09-10
CA2875351A1 (en) 2014-01-23
KR20150036092A (ko) 2015-04-07
CN104470517B (zh) 2018-12-18
ES2752034T3 (es) 2020-04-02
EP2874624B1 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
DOP2016000145A (es) Reguladores de nrf2
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
UY37410A (es) Antagonistas de trpv4
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
MX386008B (es) Compuestos citotóxicos y antimitóticos, y métodos para utilizarlos.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
MX2017000862A (es) Formulacion de factor viii.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2019007361A (es) Composiciones para el cuidado bucal.